Table 1.
Immuno-competent syngeneic murine models of glioma
| Cell line | Host | Induction | Histology | Specific and potential applications in immunotherapy | Refs |
|---|---|---|---|---|---|
| P560 |
VM/Dk |
Spontaneous |
Anaplastic Astrocytoma |
• Vaccine studies (e.g. DC) |
13, 31-38 |
| • Gene therapy studies (e.g. IL-2, CD70) | |||||
| • Reversal of immunosuppression in glioma (e.g. TGF-β) | |||||
| CT-2A |
C57BL/6 |
Chemical |
Anaplastic Astrocytoma |
• Tumor stem cells (BTSCs) |
39-63 |
| • Reversal of immunosuppression in glioma (e.g. TGF-β, PTEN) | |||||
| GL261 |
C57BL/6 |
Chemical |
GBM/Ependymoblastoma |
• Tumor stem cells (BTSCs) |
10, 35, 60, 64-99 |
| • Vaccine studies (e.g. dendritic cells) | |||||
| • Gene therapy studies (e.g. IL-2) | |||||
| • Adoptive T cell, antibody, and Treg depletion studies | |||||
| • Reversal of immunosuppression in glioma (e.g. TGF-β, PTEN) | |||||
| GL26 |
C57BL/6 |
Chemical |
GBM/Ependymoblastoma |
• Vaccine studies (e.g. dendritic cells) |
64, 66, 100-105 |
| • Gene therapy studies (e.g. IL-12) | |||||
| • Treg depletion studies | |||||
| • Chemo-immunotherapy | |||||
| 4C8 | B6D2F1 | Transgenic | Oligodendroglioma, Astrocytoma | • Vaccine studies (e.g. HSV) |
106-110 |
| • Gene therapy studies (e.g. plasmids) |
Refs = References; DC = Dendritic Cells; IL-2 = Interleukin-2; IL-12 = Interleukin-12; CD70 = Cluster of Differentiation70; TGF-β = Transforming Growth Factor-β; BTSC = Brain Tumor Stem Cell; PTEN = Phosphatase and Tensin Homolog; GBM = Glioblastoma; Treg = Regulatory T Cell; HSV = Herpes Simplex Virus.